Dr. Maura is an Assistant Member at Memorial Sloan Kettering Cancer Center, where he runs an independent research laboratory using computational and bioinformatic tools to analyze genomic and transcriptomic datasets from patients with plasma cell malignancies.

His goal is to leverage these techniques to identify signatures predictive of clinical outcomes in patients, understand mechanisms of resistance to therapies, and identify new drug targets.

Over the past years, his team has been deeply involved in modeling and integrating clinical and genomic data to track cancer genome evolution and reconstruct the chronology of early and late driver events in hematological malignancies, including multiple myeloma, lymphomas, and therapy-related myeloid neoplasms.

Despite major advances in treatment, a significant fraction of patients still experience disease progression and ultimately die. To understand why these patients do not benefit from recent therapeutic innovations—and to develop preventive strategies and personalized interventions—Dr. Maura and his collaborators have established a collaborative, multi-institutional network focused on leveraging multi-omics across diverse clinical contexts.

His mission is to execute research that informs and advances clinical practices in oncology. His team has strong expertise in clinical and genome profiling analysis, a proven track record in developing high-throughput laboratory and analytical pipelines (bioinformatics and statistical), and the ability to integrate large and complex genomic datasets.